Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Device For Hypertension After All?

This article was originally published in Start Up

Executive Summary

Despite industry-wide contraction last year after Medtronic's SYMPLICITY, many agree the trial was flawed, and some believe a hypertension device is just around the corner. A determined handful of medtech start-ups continue to pursue a device-based approach, most by reducing “fight-or-flight” outflow from the sympathetic nervous system.

You may also be interested in...



SYMPLICITY Results Make Life Difficult For Renal Denervation Programs

The big slice of the device industry, from large-cap firms to venture capitalists, with some stake in the renal denervation opportunity are trying to understand the new reality now that Medtronic’s pivotal Symplicity renal denervation device trial missed its endpoint.

CVRx: Pioneering Hypertension And Heart Failure Devices – Big Markets Take Big Funding

Starting as the first company with a device therapy for resistant hypertension, CVRx was soon competing with the renal denervation avalanche, along with trying to survive the economic collapse and a failed trial. Fortunately, the company had gotten its funding when the getting was good.

Ablative Solutions Inc.

Unlike other renal denervation technologies that apply destructive energy to the entire renal artery wall, , Ablative Solutions Inc. has developed a catheter-based approach that delivers ethanol directly to the nerves that encircle the renal artery, and destroys them without damaging the artery walls . The company is developing its Peregrine System for use in an outpatient setting to restore normal blood pressure in medication-resistant hypertensive patients.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT038038

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel